Tromboprofilaxis en COVID-19: ¿Seguimos en la neblina?

Autores/as

  • Mariano Scolari Hospital Británico de Buenos Aires

Resumen

Carta al Director de la Revista, comentando aspectos sobre la realidad cínica del manejo de los fenómenos trombóticos asociados a la infección por SARS-CoV-2.

Descargas

Los datos de descargas todavía no están disponibles.

Biografía del autor/a

Mariano Scolari, Hospital Británico de Buenos Aires

Farmacéutico de la Universidad de Buenos Aires (UBA), especialista en Farmacia Hospitalaria por la Asociación Argentina de Farmacia Hospitalaria (AAFH).

Refetente de Farmacia Clínica en el Hospital Británico de Buenos Aires.

Citas

Magro C, Mulvey J, Berlin D, Nuovo G, Salvatore S, Harp J, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infec¬tion: A report of five cases. 2020; Transl Res. doi: 10.1016/j. trsl.2020.04.007.

Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe co-ronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094-1099. https://doi.org/10.1111/ jth.14817.

Driggin E. Madhavan MV, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai, et al. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic. J Am Coll Cardiol. 2020; 75: 2352–2371.doi: 10.1016/j.jacc.2020.03.031

Hunt B,Retter A, McClintock C. Practical Guidance for the Prevention of Thrombosis and Management of Coagulopathy and Disseminated Intravascular Coagulation of Patients Infected with COVID-19; British Society for Haematology: London, England, 2020.

World Health Organization. Clinical Management of Severe Acute Respiratory Infection When Novel Coronavirus (2019- nCoV) Infection Is Suspected: Interim Guidance; WHO/ nCoV/Clinical/2020.3; World Health Organization: Geneva, Switzerland, 2020.

Wang T, Chen R, Liu C, Liang W, Guan W, Tang R, et al. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19. Lancet Haematol. 2020; doi: 10.1016/S2352-3026(20)30109-5.

Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: A multicenter prospective cohort study. Intensive Care Med. 2020; 46:1089–1098. doi: 10.1007/s00134-020-06062-x

Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Muller MCA, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J. Thromb. Haemost. 2020;18(8):1995-2002. doi: 10.1111/jth.14888.

Chi, Gerald; Lee, Jane J.; Jamil, Adeel; Gunnam, Vamsikrishna; Najafi, Homa; Montazerin, Sahar Memar; Shojaei, Fahi-mehalsadat; Marszalek, Jolanta. Venous thromboembolism among hospitalized patients with COVID-19 undergoing thromboprophylaxis: A systematic review and meta-analysis. J Clin Med. 2020; 8(9):1-17. doi:10.3390/jcm9082489.

Mattioli M, Benfaremo D, Mancini M, Mucci L, Mainquà P, Polenta A, et al. Safety of intermediate dose of low molecu¬lar weight heparin in COVID 19 patients. Journal of Thromb Thrombolysis. Published online: 13 August 2020. https://doi. org/10.1007/s11239-020-02243-z

Descargas

Publicado

2020-12-20

Cómo citar

1.
Scolari M. Tromboprofilaxis en COVID-19: ¿Seguimos en la neblina?. Ars Pharm [Internet]. 20 de diciembre de 2020 [citado 26 de abril de 2024];61(4):205-7. Disponible en: https://revistaseug.ugr.es/index.php/ars/article/view/15844

Número

Sección

Cartas al director